Cyteir Therapeutics Inc (CYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2010 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 133,900 | 151,800 | 179,300 | 415,800 | 383,300 |
| Receivables | 339,700 | 325,700 | 302,700 | 212,500 | 422,000 |
| Inventories | 307,600 | 253,100 | 269,800 | 186,500 | 350,000 |
| Income taxes - deferred | 27,400 | 32,100 | 38,400 | 34,900 | 40,600 |
| Other current assets | 26,200 | 25,100 | 428,600 | 438,100 | 115,500 |
| TOTAL | $834,800 | $787,800 | $1,218,800 | $1,287,800 | $1,311,400 |
| Non-Current Assets | |||||
| PPE Net | 1,121,400 | 1,047,000 | 835,300 | 724,700 | 1,126,200 |
| Investments And Advances | 0 | 0 | 1,700 | 0 | 19,700 |
| Intangibles | 650,400 | 682,400 | 709,000 | 326,700 | 1,032,700 |
| Other Non-Current Assets | 160,600 | 163,300 | 1,159,400 | 1,197,500 | 183,900 |
| TOTAL | $1,932,400 | $1,892,700 | $2,705,400 | $2,248,900 | $2,362,500 |
| Total Assets | $2,767,200 | $2,680,500 | $3,924,200 | $3,536,700 | $3,673,900 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,200 | 100 | 139,100 | 3,500 | 6,100 |
| Accounts payable and accrued liabilities | 172,400 | 175,700 | 176,400 | 118,900 | 263,600 |
| Accrued Expenses | 184,600 | 178,400 | 177,400 | 126,100 | 223,200 |
| Other current liabilities | N/A | N/A | 265,900 | 252,000 | 63,900 |
| TOTAL | $366,900 | $368,500 | $810,800 | $521,900 | $579,600 |
| Non-Current Liabilities | |||||
| Long Term Debt | 741,700 | 716,200 | 567,400 | 635,900 | 641,500 |
| Other Non-Current Liabilities | 416,200 | 381,900 | 670,000 | 641,300 | 641,800 |
| TOTAL | $1,189,300 | $1,130,100 | $1,310,400 | $1,321,500 | $1,357,400 |
| Total Liabilities | $1,556,200 | $1,498,600 | $2,121,200 | $1,843,400 | $1,937,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 71,282 | 71,356 | 89,651 | 91,637 | 98,902 |
| Common Shares | 1,000 | 1,000 | 500 | 500 | 500 |
| Retained earnings | 1,699,600 | 1,572,800 | 1,419,200 | 1,476,400 | 1,293,000 |
| Other shareholders' equity | 13,200 | 95,700 | 160,700 | -59,800 | -8,100 |
| TOTAL | $1,211,000 | $1,181,900 | $1,803,000 | $1,693,300 | $1,736,900 |
| Total Liabilities And Equity | $2,767,200 | $2,680,500 | $3,924,200 | $3,536,700 | $3,673,900 |